Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.92 USD | -0.54% | -0.70% | +75.73% |
Jun. 05 | Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer | CI |
Jun. 01 | Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.73% | 526M | |
+17.73% | 125B | |
+13.55% | 108B | |
-6.56% | 24.21B | |
+0.47% | 22.78B | |
-11.25% | 17.96B | |
-41.74% | 16.43B | |
-13.83% | 16.37B | |
+1.59% | 13.58B | |
+27.42% | 11.66B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024